Soluble Triggering Receptor Expressed on Myeloid Cells in Severe Acute Pancreatitis
STREM-1
2 other identifiers
observational
30
1 country
1
Brief Summary
Early diagnosis of secondary infection of necrotic tissue in severe acute pancreatitis is extremely important. The investigators evaluated whether the level of soluble TREM-1 (sTREM-1) in fine needle aspiration (FNA) fluid from patients who suspected infection is a good marker of secondary infection of necrotic tissue and an indicator of the proper treatment between drainage and necrosectomy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Jul 2008
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2008
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2009
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2009
CompletedFirst Submitted
Initial submission to the registry
August 30, 2010
CompletedFirst Posted
Study publicly available on registry
September 2, 2010
CompletedSeptember 2, 2010
September 1, 2009
1 year
August 30, 2010
September 1, 2010
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The level of sTREM-1 in fine needle aspiration fluid
The fluid level of sTREM-1 was used to diagnose the secondary infection of necrotic tissues in severe acute pancreatitis and select the proper treatment between single drainage and necrosectomy.
more than 14 days after entry
Secondary Outcomes (5)
The fluid level of Interleukin-6
more than 14 days after entry
The fluid level of tumor necrosis factor-α
more than 14 days after entry
The serum level of sTREM-1
more than 14 days after entry
The serum level of C-reactive protein
more than 14 days after entry
The level of leukocyte count and neutrophil percentage
more than 14 days after entry
Study Arms (3)
Non-infected necrosis group
There is no necrosis infection in severe acute pancreatitis.
Single drainage group
The patients with necrosis infection in severe acue pancreatitis were cured by single drainage.
Combined surgery group
If there was no clinical improvement after single drainage about 7 days, an open necrosectomy was performed in the patients with necrosis infection.
Eligibility Criteria
All patients 18 years of age or older who were hospitalized in our medical pancreatic intensive care unit (PICU) for least two weeks were enrolled in the study if there was a clinical suspicion of secondary infection of necrotic tissue.
You may qualify if:
- years of age or older
- Diagnosis of severe pancreatitis
- Pancreatic or peripancreatic necrosis
- Body temperature at least 38.3°C
- Leukocytosis (more than 10,000 leukocytes per cubic millimeter) or leukopenia (fewer than 4000 leukocytes per cubic millimeter)
You may not qualify if:
- A flare-up of chronic pancreatitis
- End-stage chronic diseases (including pancreatic and bile duct cancer)
- Previous drainage or surgery for confirmed or suspected infected necrosis
- An acute intraabdominal event (e.g., perforation of a visceral organ, bleeding, or the abdominal compartment syndrome)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Changhai Hospital, Second Military Medical University
Shanghai, 200433, China
Biospecimen
The FNA fluid specimens were performed under ultrasound or CT guidance, using a 18G needle attached to a 15 ml eppendorf tube. One percent xylocaine was used for local anaesthesia. Under real-time visualization, the needle was directed into the tissue part of the necrosis or pseudocyst.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
zhaoshen li, MD
Changhai Hospital
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
August 30, 2010
First Posted
September 2, 2010
Study Start
July 1, 2008
Primary Completion
July 1, 2009
Study Completion
November 1, 2009
Last Updated
September 2, 2010
Record last verified: 2009-09